4-24-2020

Mowat-Wilson Syndrome

Nicholas Cordell  
*Boise State University*

Jordan Council  
*Boise State University*

Crislyn Rausch  
*Boise State University*

Stephen Schott  
*Boise State University*

Julia Oxford  
*Boise State University*
Mowat-Wilson Syndrome

Abstract
Mowat-Wilson syndrome (MWS) is a rare genetic disorder that causes systemic deficiencies and abnormalities during development. Common presentations of this disorder include Hirschsprung disease (HSCR), intellectual disability, delayed development, distinctive facial features, microcephaly, epilepsy, and heart defects. Prevalence of MWS is estimated between 1/50,000 to 1/70,000 live births, with over 200 cases reported so far. MWS is likely underdiagnosed, especially in patients who do not display HSCR. Prognosis for MWS depends on the severity and presence of congenital anomalies, and few patients have been reported to live into early adulthood. Therapy may also be required to control seizures, while occupational and speech therapy may help with delayed psychomotor development which is prevalent in all patients. MWS is caused by a pathogenic variant of the ZEB2 gene that follows an autosomal dominant pattern of inheritance. A mutation of the ZEB2 gene suggests that the myelination process may represent a potential therapeutic target. Current treatments focus on symptoms, however, a potential therapeutic target may focus on the effects the mutation has on gene expression.

This student presentation is available at ScholarWorks: https://scholarworks.boisestate.edu/under_showcase_2020/31
Mowat-Wilson Syndrome
Nick Cordell, Jordan Council, Rachel Kessinger, Crislyn Rausch, Stephen Schott, Julia Oxford, Ph.D.
Department of Biological Sciences, Boise State University, Boise Idaho

Abstract
Mowat-Wilson syndrome (MWS) is a rare genetic disorder that causes systemic deficiencies and abnormalities during development. Common presentations of this disorder include Hirschsprung disease (HSCR), intellectual disability, delayed development, distinctive facial features, microcephaly, epilepsy, and heart defects. MWS is likely underdiagnosed, especially in patients who do not display HSCR. Prognosis for MWS depends on the severity and presence of congenital anomalies, and few patients have been reported to live into early adulthood. Therapy may also be required to control seizures, while occupational and speech therapy may help with delayed psychomotor development which is prevalent in all patients. MWS is caused by a pathogenic variant of the ZEB2 gene that follows an autosomal dominant pattern of inheritance. A mutation of the ZEB2 gene suggests that the myelination process may represent a potential therapeutic target. Current treatments focus on symptoms; however, a potential therapeutic target may focus on the effects the mutation has on gene expression.

Clinical Description
Common Clinical Features

Facial Features: Narrow triangular chin, deep set large eyes, broad nasal bridge, saddle nose, rounded nasal tip, open mouth, full or everted lower lip, posteriorly rotated ears, and large uplifted ear lobes with a central depression.
Nervous System: Seizures, intellectual disability, dysphagia
Musculoskeletal System: Microcephaly, short stature, slender body type, calcaneovalgus deformity.
Cardiovascular System: Congenital heart defects: abnormalities in pulmonary arteries and/or valves
Genitourinary System: Renal abnormalities, in male's hypospadias and cryptorchidism.
Digestive System: Hirschsprung disease (HSCR) and constipation
Brain Structure Deformities: Cerebral atrophy, underdeveloped hippocampus, and deformities of the temporal and frontal lobes.

Etiology
MWS is a genetic mutation affecting the ZEB2 gene located on chromosome 2. Mutations range from missense to deletions or insertions. MWS follows an autosomal dominant pattern of inheritance, one abnormal gene will cause this syndrome. Occurring de novo, neither parent is seen to have any mutation.

Diagnosis
• Diagnosed during infancy or childhood
• Identification of characteristic physical findings and facial appearance
• Computerized tomography (CT) scanning or magnetic resonance imaging (MRI) of the brain, kidney ultrasound or heart ultrasound
• Molecular genetic testing for mutations in the ZEB2 gene.
• Prenatal diagnosis for parents with an affected child

Differential Diagnosis
• Hirschsprung disease (HSCR)
• Goldberg-Shprintzen syndrome (GSS)
• Waardenburg type IV syndrome
• Smith-Lemli-Opitz syndrome
• Bardet-Biedl syndrome
• BRESHEK syndrome
• Angelman syndrome

Prognosis/Management
• Few patients reported to live into adulthood
• Prognosis depending on severity of congenital anomalies
• No cure, only treatments for symptoms
• Surgery/physical therapy for somatic symptoms (including heart, intestinal, and vascular defects)
• Speech therapy and Supportive Care
• Pharmaceuticals for constipation, GERD, and seizures

Unresolved Questions
• Other genes are involved in the agenesis of corpus callosum?
• Cause of de novo mutations?
• How are symptoms connected to deletions/mutations of ZEB2?
• Comprehensive picture of ZEB2 regulatory elements.

References

Definition
Intellectual disability characterized by distinct facial structures and may present with or without Hirschsprung’s disease. MWS was discovered in 1998 by Dr. Mowat and Dr. Wilson. Prevalence of MWS is estimated between 1/50,000 to 1/70,000 live births, with over 300 cases reported so far.

Figure 1. Progression of MWS in an individual from age 1 month to 21 years. Image credit: https://ghr.nlm.nih.gov/condition/mowat-wilson-syndrome

Figure 2. Autosomal Dominant - One Mutation

Figure 3. Image credit: https://ghr.nlm.nih.gov/primer/inheritance/riskassessment

Figure 4. Chromosome 2 location of ZEB2 gene. Image Credit: Genome Decoration Page/NCBI

Figure 5. MRI results from varying genotypes. Image Credit: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438871/